Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
CASI Pharmaceuticals Inc Market Cap
Based on ratings from 2 stock analysts, the CASI Pharmaceuticals Inc stock price is expected to increase by 57.89% in 12 months. This is calculated by using the average 12-month stock price forecast for CASI Pharmaceuticals Inc. The lowest target is $6 and the highest is $6. Please note analyst price targets are not guaranteed and could be missed completely.
CASI Pharmaceuticals Inc has a total of 2 Wall St Analyst ratings. There are 2 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that CASI Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CASI.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Sean Lee HC Wainwright & Co. | Buy | $6 | Maintains | May 15, 2024 |
| Sean Lee HC Wainwright & Co. | Buy | $12 | Maintains | Nov 15, 2023 |
| Sean Lee HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 14, 2023 |
| Sean Lee HC Wainwright & Co. | Buy | $10 | Reiterates | May 22, 2023 |
| Justin Zelin BTIG | Buy | $10 | Maintains | Nov 16, 2022 |
| Sean Lee HC Wainwright & Co. | Buy | $10 | Maintains | Nov 15, 2022 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $12 | Maintains | Aug 15, 2022 |
| Justin Zelin BTIG | Buy | $21 | Maintains | Jun 3, 2022 |
| Sean Lee HC Wainwright & Co. | Buy | $3 | Maintains | May 16, 2022 |
BTIG | Buy | Initiates | May 18, 2021 | |
| Sean Lee HC Wainwright & Co. | Buy | $4 | Maintains | May 14, 2021 |
Mizuho | Buy | Initiates | Apr 26, 2021 | |
Oppenheimer | Outperform | Initiates | Oct 23, 2020 | |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $3.5 | Maintains | Mar 24, 2020 |
Maxim Group | Buy | Initiates | Sep 22, 2016 | |
H.C. Wainwright | Buy | Initiates | Jun 23, 2015 |
When did it IPO
1996
Staff Count
176
Country
China
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Wei-Wu He Ph.D.
Market Cap
$58.8M
In 2023, CASI generated $33.9M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CASI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 15 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - CASI Pharmaceuticals reported Q3 2024 updates, emphasizing progress in developing treatments for organ transplant rejection and autoimmune diseases.
Why It Matters - CASI Pharmaceuticals' focus on organ transplant rejection and autoimmune diseases signals potential growth areas, impacting future revenue and investment attractiveness. Financial updates reflect overall performance trends.
Thu, 24 Oct 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - CASI Pharmaceuticals received approval from China's NMPA for a phase 1/2 clinical trial of CID-103 in adults with chronic Immune Thrombocytopenia, complementing a previous FDA approval.
Why It Matters - CASI Pharmaceuticals' approval for a clinical trial in China enhances its growth prospects, validates its drug development pipeline, and may positively impact stock performance and investor confidence.
Wed, 04 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - CASI Pharmaceuticals, Inc. announced its participation in the H.C. Wainwright Global Investment Conference, highlighting its focus on developing innovative therapeutics.
Why It Matters - CASI Pharmaceuticals' participation in a significant industry event may enhance visibility, attract potential partnerships, and influence stock performance through increased investor interest.
Fri, 16 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - CASI Pharmaceuticals reported Q2 2024 business updates, highlighting a strategic shift towards developing therapies for organ transplant rejection and autoimmune diseases.
Why It Matters - CASI Pharmaceuticals' strategic shift to focus on therapeutics for organ transplant rejection and autoimmune diseases may enhance growth prospects, influencing investor confidence and stock performance.
Mon, 29 Jul 2024
Sentiment - POSITIVE
Source - InvestorPlace
Summary - Biotech stocks priced under $10 are gaining attention as viable investment opportunities within the biotechnology industry.
Why It Matters - Biotech stocks under $10 may present high-growth potential at a low entry cost, attracting investors seeking affordable opportunities in a promising sector.
Fri, 19 Jul 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - CASI Pharmaceuticals, Inc. (Nasdaq: CASI) filed a Form 6-K regarding a material development in its dispute with Juventas. Further details are available on the SEC website.
Why It Matters - CASI Pharmaceuticals' dispute with Juventas could impact its operations and financial performance, influencing stock volatility and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
